Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

Table 3

Focus on biologic and quality of life.

		All	All
Variables	173	Unadjusted OR; Risk of having pathological IBDQ (≤170)	Unadjusted OR; Risk of having pathological IBD-DI (≤3.5)
Time of therapy
<6 months	53	1	1
6 months-1 year	20	0.91 (0.32-2.57)	0.89 (0.31-2.49)
1 year-5years	80	0.78 (0.38-1.59)	1.02 (0.50-2.08)
>5 years	20	0.65 (0.22-1.91)	1.53 (0.52-4.49)
Combo therapy
No	149	1	1
Yes	27	0.85 (0.37-1.97)	1.23 (0.53-2.83)
Type of biologic
Infliximab	71	1	1
Adalimumab	40	0.96 (0.43-2.12)	0.74 (0.34-1.61)
Vedolizumab	49	1.28 (0.61-2.66)	1.00 (0.48-2.09)
Golimumab	13	2.31 (0.68-7.79)	2.73 (0.69-10.78)
Type of administration
Intravenous	120	1	1
Subcutaneous	53	1.08 (0.56-2.07)	1.98 (0.51-1.89)
Type of drug
Anti-TNF	124	1	1
Anti-integrin	49	1.18 (0.60-2.30)	1.01 (0.51-1.96)

Combo therapy: AZA plus biologic therapy.